Skip to main
TOI

TOI Stock Forecast & Price Target

TOI Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Oncology Institute is projected to have a positive outlook for several reasons. The company has a strong focus on revenue-generating segments such as Specialty Pharmacy and Clinical Trials, which make up the majority of its operating segments. It also offers a wide range of oncology services to its patients, including clinical trials enrollment, making it a valuable and comprehensive resource in the healthcare industry. Additionally, with a solid performance and growth potential, Oncology Institute presents a promising investment opportunity for the future.

Bears say

Oncology Institute is a growing company that offers oncology care services, but its reliance on IV-infused specialty pharmacy and other high-cost treatments may lead to increased financial pressure and limit its ability to invest in growth. The company also has a heavy debt load and limited cash reserves, which could create refinancing risks and restrict investments. In addition, Oncology Institute faces competition from various oncology providers and risks associated with changes in healthcare legislation and reimbursement pressures. Overall, the company is trading at reasonable valuation relative to its peers, but may face challenges in sustaining its growth and profitability.

TOI has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of The Oncology Institute and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About The Oncology Institute (TOI) Forecast

Analysts have given TOI a Strong Buy based on their latest research and market trends.

According to 4 analysts, TOI has a Strong Buy consensus rating as of Jul 18, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

The Oncology Institute (TOI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.